Koers Cotinga Pharmaceuticals Inc. Toronto S.E.
Aandelen
COT.H
CA22164W1059
Biotechnologie & Medisch Onderzoek
Omzet 2018 | - | Omzet 2019 | - | Marktkapitalisatie | 1,61 mln. 2,22 mln. 1,51 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2018 | -4 mln. -5,51 mln. -3,75 mln. | Nettowinst (verlies) 2019 | -2 mln. -2,76 mln. -1,88 mln. | EV/omzet 2018 | - |
Nettoliquiditeiten 2018 | 40,73K 56,11K 38,2K | Nettoliquiditeiten 2019 | 24,64K 33,94K 23,11K | EV/omzet 2019 | - |
K/w-verhouding 2018 |
-1,11
x | K/w-verhouding 2019 |
-0,6
x | Werknemers | 6 |
Dividendrendement 2018 * |
-
| Dividendrendement 2019 |
-
| Vrij verhandelbaar | 69,18% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Alison D. Silva
PSD | President | 46 | 01-01-15 |
Debi Sanderson
COO | Chief Operating Officer | - | - |
Chief Tech/Sci/R&D Officer | 61 | 12-06-17 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 63 | 01-07-18 | |
John C. Drake
CHM | Chairman | - | 20-02-07 |
Alison D. Silva
PSD | President | 46 | 01-01-15 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-3,46% | 102 mld. | |
+1,41% | 96,29 mld. | |
+2,13% | 22,18 mld. | |
-15,84% | 21,2 mld. | |
-9,21% | 18,31 mld. | |
-39,98% | 17,38 mld. | |
-14,65% | 16,36 mld. | |
+4,39% | 13,97 mld. | |
+31,35% | 12,17 mld. |